The list price of Calquence (acalabrutinib) is \$12,500 per month for a 30-day supply of 100 mg capsules [1].
How much does a year of Calquence cost?
A year of Calquence treatment, based on the monthly list price of \$12,500, would amount to approximately \$150,000 [1]. This figure does not account for potential patient assistance programs or insurance coverage, which can significantly reduce out-of-pocket expenses.
Who makes Calquence?
Calquence is manufactured by AstraZeneca [2].
What is Calquence used for?
Calquence is a prescription medication used to treat certain types of cancer, specifically adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [3].
When does Calquence patent expire?
Information regarding the patent expiry for Calquence is available through specialized resources. DrugPatentWatch.com tracks patent data, which can provide details on when exclusivity for specific drugs is expected to end [4].
What is the difference between Calquence and other CLL/SLL treatments?
Calquence is a type of targeted therapy known as a Bruton's tyrosine kinase (BTK) inhibitor [3]. Other treatments for CLL/SLL include chemotherapy, immunotherapy, and other targeted agents, each with different mechanisms of action, efficacy, and side effect profiles. The choice of treatment depends on the specific patient and disease characteristics [3].
Can patients get financial assistance for Calquence?
Patients who require financial assistance for Calquence may be eligible for programs offered by the manufacturer. AstraZeneca provides patient support services that can help with understanding insurance coverage and accessing financial assistance programs [3].
What are the side effects of Calquence?
Common side effects of Calquence include low blood cell counts (anemia, neutropenia, thrombocytopenia), muscle and joint pain, diarrhea, rash, and headache [3]. Serious side effects can include heart rhythm problems, new or worsening high blood pressure, and secondary cancers [3].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.drugpatentwatch.com/drug/acalabrutinib
[3] https://www.calquence.com/
[4] https://www.drugpatentwatch.com/